Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2025Indian Journal of Medical and Paediatric OncologyOpen Access

Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKarthik BommannanCancer Institute (WIA)SNShano NaseemPost Graduate Institute of Medical Education and ResearchNVNeelam VarmaPost Graduate Institute of Medical Education and Research

Discussion

Loading...

Member takes

Overview

Analysis reveals hematological changes in chronic myelogenous leukemia patients on tyrosine kinase inhibitors, indicating response to therapy aligns with European Leukemia Network criteria.

Key Points

  • 90% of CML patients achieved complete hematological response by 3 months of TKI therapy, indicating effective treatment initial phase.
  • Cytopenias were common, with anemia appearing in 25% and 31% of patients at 1 and 2 years, respectively, signifying the challenges of prolonged TKI usage.
  • Observational analysis over 84 months showed marrow hypercellularity more prevalent in patients not achieving complete hematological response.
  • Findings highlight the need for careful monitoring of hematological status during long-term TKI therapy for CML patients.

Cite This Study

Bommannan et al. (2025) studied this question.

synapsesocial.com/papers/68a360e00a429f7973329170https://doi.org/10.1055/s-0045-1810082
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinico-hematological characteristic, lipogram, and some metabolic alteration in chronic phase chronic myeloid leukemia in a patient treated with Tyrosine kinase inhibitor2026
  2. 2Thyroid status in chronic phase chronic myeloid leukemia patient treated with Tyrosine Kinase Inhibitor2026
  3. 3Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network.2026
  4. 4The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity2024
  5. 5Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls2026